Expanded indication of Brineura allows for treatment of neuronal ceroid lipofuscinosis type 2 disease in both symptomatic and presymptomatic children.

A single dose of giroctocogene fitelparvovec significantly reduced the mean total annual bleeding rate in patients with moderately severe to severe hemophilia A.

Insights from Takeda, Jazz, Nestlé Health Sciences, Humana, and other healthcare executives

The latest news for pharma industry insiders.

The partnership will allow both group to expand their operations and provide more solutions to underserved communities.

The lead transformation evangelist at Celonis discusses how digital twins are becoming more prominent in the pharma industry.

Moving forward, Sage Therapeutics and Biogen intend to cease further clinical development of SAGE-324 for essential tremor.

Results of the PURPOSE 1 trial indicated that treatment with lenacapavir was superior to Descovy and Truvada.

Biocon Biologic’s chief commercial officer of advanced markets discusses the current market and potential trends for biosimilars.

The PBM defined its core values and what role it believes PBMS should play in the industry.

The latest news for pharma industry insiders.

The trial is expected to include 40 patients across the United States who haven’t responded adequately to standard hypovolemic septic shock treatments and are on vasopressors.

The new approval expands Xeomin’s indications to include horizontal forehead lines and lateral canthal lines.

The deals leader at EY Global Life Sciences discusses how the first half of 2024 fared compared to 2023’s strong ending.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.

Approval of Spravato would mark the first monotherapy to be available on the market for treatment-resistant depression in the United States.

The latest news for pharma industry insiders.

The company received the money through a government project agreement.

The AI-powered feature will provide detailed nutritional information based on photos of food taken by users.

In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how confident they are in the generalizability of these findings to a real-world treatment setting.

JAMA study aims to determine whether financial barriers impact access to mental health services.

The latest news for pharma industry insiders.

Dx&Vx identified multiple potential drug candidates using AI-based technology.

The two companies will continue to collaborate on the use of machine learning in improving precision medicine development.